BRISTOL Company Profile

✉ Email this page to a colleague

BRISTOL has one hundred and eighteen approved drugs.

There are sixty-eight US patents protecting BRISTOL drugs.

There are one thousand eight hundred and sixty-five patent family members on BRISTOL drugs in fifty-eight countries and three hundred and fifty-eight supplementary protection certificates in twenty countries.

International Patents:	1865
US Patents:	68
Tradenames:	95
Ingredients:	83
NDAs:	118
Drug Master File Entries:	1
Patent Litigation for BRISTOL:	See patent lawsuits for BRISTOL
PTAB Cases with BRISTOL as patent owner:	See PTAB cases with BRISTOL as patent owner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	METAGLIP	glipizide; metformin hydrochloride	TABLET;ORAL	021460-003	Oct 21, 2002		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Bristol	AUGTYRO	repotrectinib	CAPSULE;ORAL	218213-002	Jun 11, 2024		RX	Yes	Yes	10,294,242	⤷ Start Trial		Y		⤷ Start Trial
Bristol Myers Squibb	SERZONE	nefazodone hydrochloride	TABLET;ORAL	020152-002	Dec 22, 1994		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Bristol Myers Squibb	SERZONE	nefazodone hydrochloride	TABLET;ORAL	020152-001	Dec 22, 1994		DISCN	Yes	No		⤷ Start Trial				⤷ Start Trial
Bristol Myers Squibb	STILBESTROL	diethylstilbestrol	INJECTABLE;INJECTION	004056-004	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Bristol Myers Squibb	REMSED	promethazine hydrochloride	TABLET;ORAL	083176-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	8,530,498	⤷ Start Trial
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	7,435,745	⤷ Start Trial
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-004	Jun 29, 2006	8,288,415	⤷ Start Trial
Bristol Myers Squibb	MONOPRIL	fosinopril sodium	TABLET;ORAL	019915-004	Mar 28, 1995	4,384,123	⤷ Start Trial
Bristol	POMALYST	pomalidomide	CAPSULE;ORAL	204026-001	Feb 8, 2013	6,561,976	⤷ Start Trial
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	9,393,238	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2010-02-16
➤ Subscribe	Capsules	50 mg, 100 mg and 200 mg	➤ Subscribe	2016-11-03
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-06-14
➤ Subscribe	Tablets	30 mg	➤ Subscribe	2005-06-01
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-16
➤ Subscribe	Capsules	1 mg, 2 mg, 3 mg and 4 mg	➤ Subscribe	2017-02-08
➤ Subscribe	Capsules	50 mg and 100 mg	➤ Subscribe	2006-12-18
➤ Subscribe	Capsules	25 mg	➤ Subscribe	2010-07-12
➤ Subscribe	Capsules	150 mg	➤ Subscribe	2014-02-03
➤ Subscribe	Capsules	2.5 mg and 20 mg	➤ Subscribe	2016-07-12
➤ Subscribe	Injection	10 mg/vial	➤ Subscribe	2013-11-05
➤ Subscribe	Capsules	100 mg and 150 mg	➤ Subscribe	2010-03-19
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2009-04-09
➤ Subscribe	Nasal Spray	4 mg/spray	➤ Subscribe	2016-07-15
➤ Subscribe	Tablets	2.5 mg and 5 mg	➤ Subscribe	2016-12-28
➤ Subscribe	Tablets	20 mg, 50 mg, 70 mg and 100 mg	➤ Subscribe	2010-06-28
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-17
➤ Subscribe	Delayed-release Capsules	200 mg, 250 mg and 400 mg	➤ Subscribe	2004-06-01
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2006-09-25
➤ Subscribe	Capsules	5 mg, 10 mg and 15 mg	➤ Subscribe	2010-08-30
➤ Subscribe	For Injection Suspension	100 mg/vial	➤ Subscribe	2015-12-11
➤ Subscribe	Capsules	300 mg	➤ Subscribe	2009-07-20

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049506	201540054	Slovenia	⤷ Start Trial	PRODUCT NAME: COBICISTAT OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/13/830/001-002; DATE OF NATIONAL AUTHORISATION: 20130524; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2105135	CA 2015 00006	Denmark	⤷ Start Trial	PRODUCT NAME: POMALIDOMID OG FARMACEUTISK ACCEPTABLE SALTE, SOLVATER, HYDRATER ELLER STEREOISOMERER HERAF; REG. NO/DATE: EU/1/13/850 20130805
2782584	2021C/558	Belgium	⤷ Start Trial	PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17--ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210406
1304992	CR 2013 00053	Denmark	⤷ Start Trial	PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
0961612	09C0050	France	⤷ Start Trial	PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080111
3710439	24C1026	France	⤷ Start Trial	PRODUCT NAME: ADAGRASIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1744 20240109
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.